Abstract
The present study explored the role of the cell surface receptor Fas (CD95/APO-1) in apoptosis induced by camptothecin (CPT) in the HT29 colon carcinoma cell line. CPT-induced apoptosis was associated with high molecular weight DNA fragmentation as measured by filter elution. This fragmentation was inhibited by the caspase inhibitor, z-VAD-fmk and by cycloheximide, which also prevented proteolytic activation of caspase-3 and poly(ADP-ribose)polymerase cleavage. Under such conditions, Fas, Fas ligand, Bax, and p21 expression were increased and Fas recruited the FADD adaptor. Fas expression increase was blocked by cycloheximide but not by z-VAD-fmk, consistent with caspase activation downstream from Fas. Treatment of HT29 cells with FasL or with the CH-11 agonistic anti-Fas antibody potentiated the apoptotic response of cells treated with CPT. The anti-Fas blocking antibody ZB4 and the Fas-ligand inhibitor failed to protect HT29 cells from CPT-induced apoptosis. Such a protection was obtained by transient expression of constructs encoding a dominant-negative mutant of FADD, FADD in an antisense orientation and E8 or MC159 viral proteins that inhibit Fas-induced apoptosis at the level of FADD and procaspase-8, respectively. Together, these data show that topoisomerase I-mediated DNA damage-induced apoptosis involves activation of the Fas pathway without detectable Fas-ligand requirement in CPT-treated cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- CPT:
-
camptothecin
- CHX:
-
cycloheximide
- PARP:
-
poly (ADP-ribose) polymerase.
References
Aragane Y, Kulms D, Metze D, Wilkes G, Poppelmann B, Luger TA, Schwarz T . 1998 J. Cell. Biol. 140: 171–182
Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, Wang GH, Senkevich TG, Alnemri ES, Moss B, Lenardo MJ, Tomaselli KJ, Cohen JI . 1997 Proc. Natl. Acad. Sci. USA 94: 1172–1176
Bertrand R, Kohn KW, Solary E, Pommier Y . 1995 Drug Development Res. 34: 138–144
Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y . 1994 Exp. Cell Res. 211: 314–321
Chan FK-M, Chun HJ, Zhen L, Siegel RM, Bui KL, Lenardo MJ . 2000 Science 288: 2351–2354
Chen AY, Liu LF . 1994 Annu. Rev. Pharmacol. Toxicol. 94: 194–218
Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E . 1995 Leukemia 9: 1013–1024
Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH . 1997 Blood 90: 935–943
Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B . 2000 J. Immunol 164: 5023–5027
Friesen C, Herr I, Krammer PH, Debatin KM . 1996 Nat. Med. 2: 574–577
Goldwasser F, Bae IS, Torres K, Pommier Y . 1995 Cancer Res. 55: 2116–2121
Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, Pommier Y . 1996 Cancer Res. 56: 4430–4437
Gunthert AR, Strater J, von Reyher U, Henne C, Joos S, Koretz K, Moldenhaue RG, Krammer PH, Moller P . 1996 J. Cell. Biol. 134: 1089–1096
Houghton JA, Harwood FG, Tillman DM . 1997 Proc. Natl. Acad. Sci. USA 94: 8144–8149
Khodarev NN, Sokolova IA, Vaughan AT . 1998 Int. J. Radiat Biol. 73: 455–467
Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M, Daniel PT, Knipping E, Westendorp MO . 1994 Immunol Rev. 142: 175–191
Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS.-S, Flavell RA . 1995 Science 267: 2000–2006
Memon SA, Hou J, Moreno MB, Zacharchuk CM . 1998 J. Immunol 160: 2046–2049
Micheau O, Solary E, Hamman A, Dimanche-Boitrel M.-T . 1999 J. Biol. Chem. 274: 7987–7992
Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT . 1997 J. Natl. Cancer 89: 783–789
Miyashita T, Reed JC . 1995 Cell 80: 293–299
Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A, Krammer PH . 1994 Int. J. Cancer 57: 371–377
Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM . 1996 Cell 85: 817–827
Nagata S, Golstein P . 1995 Science 267: 1449–1456
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik Y, Munday NA, Raju SM, Smulson ME, Yamin T.-T, Yu V, Miller DK . 1995 Nature 376: 37–43
O'Connell J, O'Sullivan GC, Collins JK, Shanahan F . 1996 J. Exp. Med. 184: 1075–1082
O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, Pommier Y . 1991 Cancer Commun. 3: 233–240
O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Jr AJ, Kohn KW . 1997 Cancer Res. 57: 4285–4300
Oberhammer FA, Hochegger K, Froschl G, Tiefenbacher R, Pavelka M . 1994 J. Cell Biol. 126: 827–837
Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhan WW, Kruzel E, Radinsky R . 1995 Mol. Cell. Biol. 15: 3032–3040
Pommier Y, Pourquier P, Fan Y, Strumberg D . 1998 Biochim. Biophys. Acta 1400: 83–105
Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV, Lane DP . 1990 Proc. Natl. Acad. Sci. USA 87: 7555–7559
Rusnak JM, Calmels TP, Hoyt DG, Kondo Y, Yalowich JC, Lazo JS . 1996 Mol. Pharmacol. 49: 244–252
Shao R.-G, Cao C.-X, Zhang H, Kohn KW, Wold MS, Pommier Y . 1999 EMBO J. 18: 1397–1406
Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y . 1997a Cancer Res. 57: 4029–4035
Shao RG, Shimizu T, Pommier Y . 1996 Exp. Cell Res. 227: 190–196
Shao RG, Shimizu T, Pommier Y . 1997b Exp. Cell Res. 234: 388–397
Shimizu T, O'Connor PM, Kohn KW, Pommier Y . 1995 Cancer Res. 55: 228–231
Siegel RM, Frederiksen JK, Zacharias DA, Chan FK-M, Johnson M, Lynch D, Tsien RY, Lenardo MJ . 2000 Science 288: 2345–2357
Strumberg D, Pilon AA, Smith M, Hickey R, Malkas L, Pommier Y . 2000 Mol. Cell Biol. 20: 3977–3987
Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyosh IK, Mizuke M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S . 1996 Nat. Med. 2: 317–322
Tillman DM, Harwood FG, Gibson AA, Houghton JA . 1998 Cell Death Differ. 5: 450–457
Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R . 1997 Cancer Res. 57: 3331–3334
Zhan Q, El-Deiry W, Bae I, Alamo Jr I, Kastan MB, Vogelstein B, Fornace JAJ . 1995 Int. J. Oncol. 6: 937–946
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shao, RG., Cao, CX., Nieves-Neira, W. et al. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene 20, 1852–1859 (2001). https://doi.org/10.1038/sj.onc.1204264
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204264
Keywords
This article is cited by
-
“pH-triggered” drug release using shell cross-linked micelles from aqueous RAFT-synthesized PAPMA-b-PNIPAM copolymers
Journal of Polymer Research (2018)
-
Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug
Scientific Reports (2017)
-
Crocetin exploits p53-induced death domain (PIDD) and FAS-associated death domain (FADD) proteins to induce apoptosis in colorectal cancer
Scientific Reports (2016)
-
Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways
Apoptosis (2013)
-
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer
Medical Oncology (2013)